Skip to main content

Table 1 Detailed patient characteristics of 52 patients treated with Lu-177-PSMA-617 RLT

From: Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy

Characteristic

Subgroup

No. of patients

Percentage

Number of treatment cycles applied

1 treatment cycle

15/52

28.8

 

2 treatment cycles

11/52

21.2

 

3 treatment cycles

5/52

9.6

 

4 treatment cycles

16/52

30.8

 

5 treatment cycles

1/52

1.9

 

6 treatment cycles

3/52

5.8

 

7 treatment cycles

1/52

1.9

Systemic pretreatment prior to Lu-177-PSMA-617 radioligand therapy

Bicalutamide and/or Leuprorelin

48/52

92.3

 

Enzalutamide and/or Abiraterone

44/52

84.6

 

Chemotherapy (Docetaxel or Cabazitaxel)

39/52

75.0

 

Ra-223-Dichloride

8/52

15.4

Local-regional pretreatment prior to Lu-177-PSMA-617 radioligand therapy

Radical prostatectomy

33/52

63.5

 

External beam radiation and/or Brachytherapy

39/52

75.0

Location of metastases in pre-therapeutic Ga-68-PSMA-PET/CT scan

Skeletal

52/52

100.0

 

Lymphatic

42/52

80.8

 

Hepatic

9/52

17.3

 

Cerebral

3/52

5.8

 

Pulmonary

3/52

5.8

 

Median

Range

Age at 1st treatment cycle

72.1 years

56.3–84.6 years